Clinical Trial: Safety and Early Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06976229) titled 'Safety and Early Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial' on May 08.

Brief Summary: The goal of this clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of iPSC-derived motor neuron progenitor cells (iMNP) in the treatment of spinal cord injury (SCI) in adult participants (age and sex criteria as per inclusion/exclusion criteria). The main questions it aims to answer are:

Primary Safety & Tolerability (Phase I): What is the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) profile of iMNP transplantation in SCI patients?

Participant...